Literature DB >> 11527968

Erythrocyte ankyrin promoter mutations associated with recessive hereditary spherocytosis cause significant abnormalities in ankyrin expression.

P G Gallagher1, D E Sabatino, D S Basseres, D M Nilson, C Wong, A P Cline, L J Garrett, D M Bodine.   

Abstract

Ankyrin defects are the most common cause of hereditary spherocytosis (HS). In several kindreds with recessive, ankyrin-deficient HS, mutations have been identified in the ankyrin promoter that have been proposed to decrease ankyrin synthesis. We analyzed the effects of two mutations, -108T to C and -108T to C in cis with -153G to A, on ankyrin expression. No difference between wild type and mutant promoters was demonstrated in transfection or gel shift assays in vitro. Transgenic mice with a wild type ankyrin promoter linked to a human (A)gamma-globin gene expressed gamma-globin in 100% of erythrocytes in a copy number-dependent, position-independent manner. Transgenic mice with the mutant -108 promoter demonstrated variegated gamma-globin expression, but showed copy number-dependent and position-independent expression similar to wild type. Severe effects in ankyrin expression were seen in mice with the linked -108/-153 mutations. Three transgenic lines had undetectable levels of (A)gamma-globin mRNA, indicating position-dependent expression, and four lines expressed significantly lower levels of (A)gamma-globin mRNA than wild type. Two of four expressing lines showed variegated gamma-globin expression, and there was no correlation between transgene copy number and RNA level, indicating copy number-independent expression. These data are the first demonstration of functional defects caused by HS-related, ankyrin gene promoter mutations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11527968     DOI: 10.1074/jbc.M105844200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Mutation of a barrier insulator in the human ankyrin-1 gene is associated with hereditary spherocytosis.

Authors:  Patrick G Gallagher; Laurie A Steiner; Robert I Liem; Ashley N Owen; Amanda P Cline; Nancy E Seidel; Lisa J Garrett; David M Bodine
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

2.  An insulator with barrier-element activity promotes alpha-spectrin gene expression in erythroid cells.

Authors:  Patrick G Gallagher; Douglas G Nilson; Laurie A Steiner; Yelena D Maksimova; Jolinta Y Lin; David M Bodine
Journal:  Blood       Date:  2008-11-13       Impact factor: 22.113

3.  Functional analysis of a novel cis-acting regulatory region within the human ankyrin gene (ANK-1) promoter.

Authors:  Karina Laflamme; Ashley N Owen; Emily E Devlin; Mary Q Yang; Clara Wong; Laurie A Steiner; Lisa J Garrett; Laura Elnitski; Patrick G Gallagher; David M Bodine
Journal:  Mol Cell Biol       Date:  2010-05-17       Impact factor: 4.272

4.  Variegated expression from the murine band 3 (AE1) promoter in transgenic mice is associated with mRNA transcript initiation at upstream start sites and can be suppressed by the addition of the chicken beta-globin 5' HS4 insulator element.

Authors:  Tiffany F Frazar; Jessica L Weisbein; Stacie M Anderson; Amanda P Cline; Lisa J Garrett; Gary Felsenfeld; Patrick G Gallagher; David M Bodine
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

5.  A tissue-specific chromatin loop activates the erythroid ankyrin-1 promoter.

Authors:  Ashley O Yocum; Laurie A Steiner; Nancy E Seidel; Amanda P Cline; Emily D Rout; Jolinta Y Lin; Clara Wong; Lisa J Garrett; Patrick G Gallagher; David M Bodine
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

6.  Genome-wide detection of a TFIID localization element from an initial human disease mutation.

Authors:  Mary Q Yang; Karina Laflamme; Valer Gotea; Clinton H Joiner; Nancy E Seidel; Clara Wong; Hanna M Petrykowska; Jens Lichtenberg; Stephen Lee; Lonnie Welch; Patrick G Gallagher; David M Bodine; Laura Elnitski
Journal:  Nucleic Acids Res       Date:  2010-11-11       Impact factor: 16.971

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.